Open AccessClinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy
Author(s) -
Ying Zheng,
Yasuyuki Takata,
Rachel H. Mackey,
Julie Gayle,
Christina L. Wassel,
Hemant Phatak,
Ruth Kim
Publication year - 2021
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s290768
Subject(s) - medicine , merkel cell carcinoma , chemotherapy , adverse effect , comorbidity , oncology , observational study , retrospective cohort study , cancer , carcinoma
Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with poor prognosis. This study compared patient characteristics, comorbidities, adverse events (AEs), treatment persistence, healthcare resource utilization (HRU) and costs in patients with metastatic MCC (mMCC) treated with immune checkpoint inhibitors (ICIs) or recommended chemotherapy per 2018 National Comprehensive Cancer Network (NCCN) Guidelines.